USPTO serial 86600429
ADVEON
Reviewed by CopyMark Law Group
Status 605
- Filing date
- Status date
- Registration date
- —
- Examiner
- HACK, ANDREA R
- Law office
- GENERIC WEB UPDATE
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ADVEON?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
COOLOCK, DUBLIN 17, IE
Other trademarks owned by ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Fajardo, PR
Fajardo, PR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Matthew O. Brady
MATTHEW O. BRADY Warner Chilcott Company Llc400 Interpace PkwyParsippany, NJ 07054-1120UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Oral, transdermal, injectable and intravaginal contraceptives; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medicines for the urogenital organs; Pharmaceuticals and medicines for the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungals; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; pharmaceutical preparations for use as a neuroprotective agent; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
- Other trademarks owned by Warner Chilcott Company, LLC
- Other trademarks owned by Warner Chilcott Company, LLC
- Other trademarks in Class 005
- Similar marks named ADVEON
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 19, 2020 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jun 21, 2017 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Nov 4, 2015 | MAB5 | ABANDONMENT NOTICE MAILED - AFTER PUBLICATION | — |
| Nov 4, 2015 | ABN5 | ABANDONMENT - AFTER PUBLICATION | — |
| Nov 2, 2015 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Oct 12, 2015 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Sep 15, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 15, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 26, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 13, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 7, 2015 | ALIE | ASSIGNED TO LIE | — |
| Jul 27, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 27, 2015 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 27, 2015 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2015 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2015 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 24, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 24, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 20, 2015 | NWAP | NEW APPLICATION ENTERED | — |